Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 24
1991 73
1992 138
1993 227
1994 228
1995 311
1996 338
1997 348
1998 375
1999 383
2000 404
2001 437
2002 507
2003 460
2004 427
2005 438
2006 399
2007 372
2008 370
2009 383
2010 394
2011 444
2012 435
2013 429
2014 418
2015 410
2016 315
2017 309
2018 318
2019 333
2020 313
2021 345
2022 297
2023 270
2024 87

Text availability

Article attribute

Article type

Publication date

Search Results

10,840 results

Results by year

Filters applied: . Clear all
Page 1
Clinical pharmacokinetics of losartan.
Sica DA, Gehr TW, Ghosh S. Sica DA, et al. Clin Pharmacokinet. 2005;44(8):797-814. doi: 10.2165/00003088-200544080-00003. Clin Pharmacokinet. 2005. PMID: 16029066 Review.
Losartan is the first orally available angiotensin-receptor antagonist without agonist properties. ...Losartan, or its E 3174 metabolite, is not removed during haemodialysis. ...
Losartan is the first orally available angiotensin-receptor antagonist without agonist properties. ...Losartan, or its E 3174 …
Losartan: Comprehensive Profile.
Al-Majed AR, Assiri E, Khalil NY, Abdel-Aziz HA. Al-Majed AR, et al. Profiles Drug Subst Excip Relat Methodol. 2015;40:159-94. doi: 10.1016/bs.podrm.2015.02.003. Epub 2015 Apr 9. Profiles Drug Subst Excip Relat Methodol. 2015. PMID: 26051686 Review.
Losartan (Cozaar) is an angiotensin II receptor antagonist with antihypertensive activity. ...Physical characteristics including: ionization constant, solubility, X-ray powder diffraction pattern, thermal methods of analysis, UV spectrum, IR spectrum, mass spectrum with fr …
Losartan (Cozaar) is an angiotensin II receptor antagonist with antihypertensive activity. ...Physical characteristics including: ion …
Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma.
Regan DP, Chow L, Das S, Haines L, Palmer E, Kurihara JN, Coy JW, Mathias A, Thamm DH, Gustafson DL, Dow SW. Regan DP, et al. Clin Cancer Res. 2022 Feb 15;28(4):662-676. doi: 10.1158/1078-0432.CCR-21-2105. Clin Cancer Res. 2022. PMID: 34580111 Free PMC article.
Here we leverage dogs with spontaneous OS to determine losartan's safety and pharmacokinetics associated with monocyte pharmacodynamic endpoints, and assess its antitumor activity, in combination with the kinase inhibitor toceranib. ...Losartan PK and monocyt …
Here we leverage dogs with spontaneous OS to determine losartan's safety and pharmacokinetics associated with monocyte pharmac …
The effects of losartan or angiotensin II receptor antagonists on cartilage: a systematic review.
Yamaura K, Nelson AL, Nishimura H, Rutledge JC, Ravuri SK, Bahney C, Philippon MJ, Huard J. Yamaura K, et al. Osteoarthritis Cartilage. 2023 Apr;31(4):435-446. doi: 10.1016/j.joca.2022.11.014. Epub 2022 Dec 28. Osteoarthritis Cartilage. 2023. PMID: 36586717 Free article. Review.
OBJECTIVE: The aim of this study is to analyze the latest evidence on the effects of losartan or Ang II receptor antagonists on cartilage repair, with a focus on their clinical relevance. DESIGN: The PubMed, Embase, and Cochrane Library databases were searched up to Novemb …
OBJECTIVE: The aim of this study is to analyze the latest evidence on the effects of losartan or Ang II receptor antagonists on carti …
[Losartan].
Quetglas EG, Sádaba B, Escolar M, Honorato J. Quetglas EG, et al. Rev Med Univ Navarra. 1997 Jul-Sep;41(3):193-7. Rev Med Univ Navarra. 1997. PMID: 10420926 Review. Spanish. No abstract available.
Pharmacokinetic evaluation of losartan.
Burnier M, Wuerzner G. Burnier M, et al. Expert Opin Drug Metab Toxicol. 2011 May;7(5):643-9. doi: 10.1517/17425255.2011.570333. Epub 2011 Mar 22. Expert Opin Drug Metab Toxicol. 2011. PMID: 21417956 Review.
As the first angiotensin II receptor blocker (ARB) on the market, losartan belongs to the most frequently prescribed ARB. AREA COVERED: The present review examines the pharmacokinetics of losartan with a special discussion on the dose of losartan that should …
As the first angiotensin II receptor blocker (ARB) on the market, losartan belongs to the most frequently prescribed ARB. AREA COVERE …
Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models.
Datta M, Chatterjee S, Perez EM, Gritsch S, Roberge S, Duquette M, Chen IX, Naxerova K, Kumar AS, Ghosh M, Emblem KE, Ng MR, Ho WW, Kumar P, Krishnan S, Dong X, Speranza MC, Neagu MR, Iorgulescu JB, Huang RY, Youssef G, Reardon DA, Sharpe AH, Freeman GJ, Suvà ML, Xu L, Jain RK. Datta M, et al. Proc Natl Acad Sci U S A. 2023 Feb 7;120(6):e2219199120. doi: 10.1073/pnas.2219199120. Epub 2023 Feb 1. Proc Natl Acad Sci U S A. 2023. PMID: 36724255 Free PMC article.
Used in lieu of immunosuppressive corticosteroids, the angiotensin receptor blocker losartan prevented this ICB-induced edema and reprogrammed the tumor microenvironment, curing 20% of mice which increased to 40% in combination with standard of care treatment. Using a bihe …
Used in lieu of immunosuppressive corticosteroids, the angiotensin receptor blocker losartan prevented this ICB-induced edema and rep …
The effect of losartan on the development of post-traumatic joint stiffness in a rat model.
Wegner E, Mickan T, Truffel S, Slotina E, Müller L, Wunderlich F, Harper A, Ritz U, Rommens PM, Gercek E, Drees P, Baranowski A. Wegner E, et al. Biomed Pharmacother. 2023 Oct;166:115291. doi: 10.1016/j.biopha.2023.115291. Epub 2023 Aug 7. Biomed Pharmacother. 2023. PMID: 37557010 Free article.
Pharmacotherapy with losartan or placebo (30 mg/kg/day) was initiated on the day of trauma and continued for the entire course. ...During the re-mobilization phase, no significant effect of losartan on range of motion (ROM) was demonstrated. At a cellular level, …
Pharmacotherapy with losartan or placebo (30 mg/kg/day) was initiated on the day of trauma and continued for the entire course. ...Du …
Losartan Interactions with 2-Hydroxypropyl-beta-CD.
Palli V, Leonis G, Zoupanou N, Georgiou N, Chountoulesi M, Naziris N, Tzeli D, Demetzos C, Valsami G, Marousis KD, Spyroulias GA, Mavromoustakos T. Palli V, et al. Molecules. 2022 Apr 8;27(8):2421. doi: 10.3390/molecules27082421. Molecules. 2022. PMID: 35458617 Free PMC article.
Losartan potassium salt (LSR) is a well-known antihypertensive drug with proven beneficial effects on human health. ...
Losartan potassium salt (LSR) is a well-known antihypertensive drug with proven beneficial effects on human health. ...
10,840 results
You have reached the last available page of results. Please see the User Guide for more information.